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Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in the
treatment of peritoneal carcinomatosis from gastrointestinal malignancies. The purpose of this study is to reevaluate the incidence
of gastrointestinal events and identify risk factors associated with this treatment approach. Between January 1, 2006 and December
31, 2009, 147 patients with appendiceal and colorectal carcinomatosis were treated. Gastrointestinal events were analyzed. The
overall incidence of grade I–IV gastrointestinal events was 17%. There were 4 grade III gastrointestinal events that occurred in
4 patients and 11 grade IV gastrointestinal events that occurred in 8 patients. On univariate analysis of grade I–IV events a
statistically signiﬁcant association was observed with the following variables: histological grade, peritoneal cancer index (PCI),
small bowel resection, colorectal anastomosis, and the number of anastomoses performed per patient. By multivariate analysis,
PCI was identiﬁed as the only independent risk factor for gastrointestinal complications. CRS combined with a uniform HIPEC
regimen is associated with a 17% gastrointestinal morbidity rate (grade I–IV). The frequency of gastrointestinal complications was
associated with a large extent of disease measured by PCI (>30).
1.Introduction
In the past, peritoneal carcinomatosis (PC) was considered
asaﬁnalstageofunresectablecancerwithashortdurationof
survival [1–3]. Since the mid 1990s, studies on CRS combi-
nedwithperioperativeintraperitonealchemotherapy(PIC),
hyperthermic intraperitoneal chemotherapy (HIPEC), and/
or early postoperative intraperitoneal chemotherapy (EPIC)
are considered a new treatment options for selected patients
with PC and peritoneal mesothelioma [4–12].
As the surgical technology has improved and the regi-
mensforadministeringchemotherapyhavebecomesafer,the
complications associated with this treatment approach have
decreased [13–18]. In a systematic review, Chua reviewed all
the relevant studies reported before August 2008 and con-
cluded that the morbidity and mortality of CRS and HIPEC
were similar to other major gastrointestinal interventions
[19]. An important concept, “the learning curve,” has been
demonstrated to operate in the expanded application of CRS
and HIPEC [20–22]. Smeenk et al. reported the results of
323 procedures over a 10-year time period; they showed a
decrease in major morbidity from 71% to 34% [22]. Yan et
al. demonstrated a reduction in the rate of severe morbidity,
transfusion requirement, duration of operation, and length
of intensive care unit stay over a similar period of time in 140
patients [21].
In recent publications overall grade III-IV morbidity
rates are shown to be between 7 and 41% [23–26]. For
gastrointestinal events, small bowel perforations and anas-
tomotic leaks are the most common and clinically signiﬁcant2 International Journal of Surgical Oncology
complications after CRS and PIC [23–27]. The aim of this
study was to report the incidence of gastrointestinal events
and identify the associated risk factors.
2.MaterialsandMethods
2.1.PatientCharacteristics. Allpatientswithappendicealand
colorectal carcinomatosis treated in a uniform manner at
Washington Hospital Center, between January 1, 2006 and
December 31, 2009 constituted the basis of the present study.
Institutional Review Board approval was obtained to collect
and analyze these data. All patients with appendiceal and
colorectal malignancy who received CRS combined with a
standardized treatment with PIC were included (Table 1).
Patients who had an incomplete CRS combined with PIC
were included in the study, patients who had an open and
close procedure or palliative debulking were not included.
The quantitative prognostic indicators were the histological
grade, the prior surgical score (PSS), the peritoneal cancer
index (PCI), and the completeness of cytoreduction score
(CC) [28].
2.2. Cytoreductive Surgery and Perioperative Intraperitoneal
and Systemic Chemotherapy. The goal of surgery in these
patientswastovisiblycleartheabdomenandpelvisofcancer
nodules. This required a series of peritonectomy procedures
and visceral resections (Table 1). Normal peritoneum or
normal visceral structures were not resected. A mechanical
bowel preparation was used in all patients. Within one hour
prior to the abdominal incision, patients received antibi-
otic prophylaxis. Prophylaxis for venous thrombosis and
pulmonary embolus during the cytoreductive surgery was
limited to sequential compression devices (SCD Response,
Kendall Co., Mansﬁeld, MA).
All patients received HIPEC in the operating room
immediately after the CRS but before intestinal anastomoses
or repair of seromuscular tears. A combination of two
drugs was administered intraperitoneally: mitomycin C
(15mg/m2)a n dd o x o r u b i c i n( 1 5 m g / m 2). The target tem-
perature for the entire abdomen during HIPEC was 41.5◦C.
Simultaneously,intravenous5-ﬂuorouracil(400mg/m2)and
leucovorin(20mg/m2)wereadministeredasarapidinfusion
over 6–8 minutes. HIPEC was given using the Coliseum
technique [29]. A heater circulator (Belmont Instruments
Corporation, Billerica, MA) was used to maintain moderate
hyperthermia within the abdomen and pelvis (41–43◦C).
During the ﬁrst 45 minutes, only manual distribution of
the chemotherapy solution occurred. In the second 45
minutes of the 90-minute treatment, seromuscular tears
were repaired, the anterior and posterior rectus sheath were
brought together with a running 2-0 Vicryl suture (Ethicon,
Cincinnati, OH), and chest tubes were positioned.
Esophago-jejunal and colorectal anastomoses were per-
formed with a 28mm or 33mm diameter circular stapler,
respectively (Ethicon, Cincinnati, OH). Esophago-jejunal
anastomoses were reinforced with a layer of silk sutures. If
the colorectal stapled anastomoses could be well visualized,
a second layer of 3–0 silk sutures was used to plicate the
anastomosis.Ifthisdoublelayeranastomosiswasperformed,
Table 1: Patients characteristics, quantitative prognosis indicators,
peritonectomies, visceral resections, and intraoperative treatments.
Variable n
Total Patients 147
Gender
Male 68 (46%)
Female 79 (54%)
Age at the time of surgery (years)
Mean ± 1 Standard Deviation 49.9 (±8.7)
Median 51
Range 23–64
Primary cancer diagnosis
Appendiceal cancer 135 (92%)
Colorectal cancer 12 (8%)
Histological grade
Grade 1 61 (41.6%)
Grade 2 12 (8%)
Grade 3 74 (50.4%)
Prior surgical score
0–2 133 (90.5%)
3 14 (9.5%)
Peritoneal cancer index
0–10 31 (21%)
11–20 40 (27%)
21–30 53 (36%)
31–39 23 (16%)
Completeness of cytoreduction
Complete 125 (85%)
Incomplete 22 (15%)
Peritonectomy procedures
Pelvic 123 (84%)
Right upper quadrant 109 (74%)
Left upper quadrant 72 (49%)
Omental bursa 70 (48%)
Anterior abdominal wall 50 (34%)
Peritonectomy procedures per
patient
zero 18 (12%)
one 21 (14%)
two 16 (11%)
three 29 (20%)
four 31 (21%)
ﬁve 32 (22%)
Visceral resections performed
Greater omentectomy 144 (98%)
Splenectomy 84 (57%)
Rectosigmoid colon resection 70 (48%)
Right colon resection 57 (39%)
Hysterectomy 47 (32%)International Journal of Surgical Oncology 3
Table 1: Continued.
Variable n
Small bowel resection 29 (20%)
Transverse colon resection 20 (14%)
Gastrectomy 4 (3%)
Visceral resections per patient
Zero 2 (1.4%)
One 20 (13.6%)
Two 34 (23.1%)
Three 34 (23.1%)
Four 32 (21.8%)
Five 15 (10.2%)
Six 8 (5.4%)
Seven 2 (1.4%)
Anastomoses performed
Esophageal 2 (1.4%)
Small bowel 22 (15.0%)
Ileocolic 29 (19.7%)
Colocolic 3 (2.0%)
Colorectal 56 (38.1%)
A n a s t o m o s e sp e r f o r m e dp e rp a t i e n t
Zero 74 (50.3%)
One 44 (29.9%)
Two 21 (14.3%)
Three 6 (4.1%)
Four 2 (1.4%)
Ostomies performed
Diverting ileostomy 30 (20.4%)
End ileostomy 13 (8.8%)
None 67 (70.8%)
Blood replacement
None 39 (26.5%)
Blood 1–3 68 (46.3%)
Blood 4–6 35 (23.8%)
Blood > 65 ( 3 . 4 % )
Fresh frozen plasma replacement
None 80 (54.4%)
Plasma 1–4 51 (34.7%)
Plasma >4 16 (10.9%)
Time in operating room (hours)
0–6 10 (6.89%)
6–12 124 (84.4%)
> 12 13 (8.8%)
Chemotherapy treatments
HIPEC only 82 (55.8%)
HIPEC plus EPIC 65 (44.2%)
no diverting ostomy was constructed. If the colorectal
anastomosiswastoolowtoplaceasecondlayerofsilksutures
over the circular stapled anastomosis, a diverting ostomy
was constructed. All small bowel, colo-colic and ileocolic
anastomoses were double-layer hand sewn with an inner
layer of running 3-0 Maxon (Davis and Geck, Danbury, CT)
and interrupted outer layer of 3-0 silk.
2.3.EarlyPostoperativeIntraperitonealChemotherapy(EPIC).
The EPIC 5-ﬂuorouracil (5-FU) was withheld in patients,
who had a full course of oxaliplatin-based FOLFOX
chemotherapy prior to CRS. The dose of EPIC 5-FU was
400mg/m2/day for women and 600mg/m2/day for men. It
was infused via a Tenckhoﬀ c a t h e t e ro v e ra p p r o x i m a t e l y
15 minutes with a 23-hour dwell time. After one hour of
drainage,anotheradministrationof5-FUoccurredfor4days
after surgery.
2.4. Postoperative Management. Patients were transferred
directly to a surgical intensive care unit for monitoring
and extubation. An 18 French nasogastric tube (Silicone
Salem Sump Tube, Kendall Co., Mansﬁeld, MA) was placed
intraoperatively in all patients and remained until the
drainage of bile from the stomach has ceased and some
enteric function per rectum or per ostomy had occurred. All
patients received postoperative intravenous feeding through
the intrajugular vein for the ﬁve postoperative days and then
through a percutaneous central catheter (Vaxcel, Glen Falls,
NY) until gastrointestinal function returned. Closed suction
drains remained in place after surgery in all patients until
drainage was below 50 mL per 24 hours from a single drain.
2.5. Database for Morbidity Assessment. The database was
specially constructed to evaluate gastrointestinal complica-
tions in patients with peritoneal surface malignancy. The
morbidityvariableswereprospectivelyrecordedaccordingto
the Common Toxicity Criteria (version 3.0) of the National
Cancer Institute [30]. It consisted of 11 gastrointestinal
adverseevents(anastomoticfailure,ﬁstula,pancreaticﬁstula,
pancreatitis, bile leak, chyle leak, prolonged ileus, small
bowel obstruction, nausea/vomiting, diarrhea and ascites).
Types of gastrointestinal adverse events observed and the
grade are listed in Table 2.
The following clinical variables were analyzed to asses
factors predictive of gastrointestinal complications: gender,
age (≤50 versus >51), primary cancer location, grade (grade
1 versus grade 2-3), prior surgical score (0–2 versus 3–5),
peritoneal cancer index (0–10, 11–20, 21–30, 31–39, and 0-
20 versus 31–39), completeness of cytoreduction (complete
versus incomplete), peritonectomy procedures (pelvic,
right upper quadrant, left upper quadrant, omental bursa,
and anterior abdominal wall), number of peritonectomy
procedures per patient (0–2 versus 3–5), visceral resections
performed (omentectomy, splenectomy, rectosigmoid colon
resection, right colon resection, hysterectomy, small bowel
resection, transverse colon resection, and gastrectomy),
visceral resections performed per patient (0–2 versus 3–
7), types of anastomoses performed (esophago-jejunal,
small bowel, ileocolic, colocolic, and colorectal), number4 International Journal of Surgical Oncology
Table 2: The total number of gastrointestinal adverse events grade I through grade IV.
Organ System Grade I-Asymptomatic
and self-limiting
Grade II-Symptomatic
and medical treatment
Grade III-Invasive
intervention
G r a d eI V - I C Uc a r eo r
return to operating
room
Gastrointestinal System N = 5 N = 15 N = 4 N = 11
Anastomotic failure Sub-clinical, afebrile,
radiologic diagnosis (0) Antibiotics, febrile (0) Percutaneous drainage
(0) Reoperation (3)
Fistula Sub-clinical, afebrile,
radiologic diagnosis (0) Antibiotics, febrile (0) Percutaneous drainage
(0) Reoperation (3)
Pancreatic ﬁstula Elevated enzymes in
drains (0)
TPN and somatostatin
(0)
Percutaneous drainage
(0) Reoperation (1)
Pancreatitis Elevated enzymes (4) ≤3 Ranson’s score (4) 4–6 Ranson’s score (0) Reoperation/ICU (1)
Bile leak Bile only in drain (0) Bile in drain, febrile (2) Percutaneous drainage
(0) Reoperation (1)
Chyle leak Transient (1) Prolonged 1 week (0) Cease prior to
discharge (0)
Persist past hospital
discharge (0)
Prolonged ileus N/G (0) N/G > 2w e e k s( 1 ) N / G>3w e e k s( 0 ) Persist past hospital
discharge (0)
Small bowel obstruction Abdominal pain (0) Abdominal pain, N/G
reinsertion (0)
Repeat radiologic
studies (0) Reoperation (1)
Nausea/vomiting Transient vomiting (0) Vomiting, anti-emetics
(7)
Vomiting, IV therapy
(4)
Vomiting with surgical
intervention or ICU (1)
Diarrhea Transient <2d a y s( 0 ) Tolerable, but >2d a y s
(1)
Intolerable, IV therapy
(0)
Dehydration prolonged
IV therapy (0)
Ascites Mild (0) Fluid restriction (0) Symptomatic,
percutaneous tap (0)
Compromising vital
function, ICU care (0)
of anastomoses performed per patient (0–2 versus 3–5),
ostomies performed (none, diverting ileostomy and end
ileostomy), blood replacement (none, 1–3 units, 4–6 units,
>6 units), fresh frozen plasma replacement (none, 1–4 units,
>4 units), time in the operating room in hours (0–6, 7–12,
>12), and chemotherapy treatment (HIPEC only versus
HIPEC plus EPIC).
2.6. Statistical Methods. For univariate methods to assess the
association between gastrointestinal complications and pre-
and perioperative clinical characteristics, the Pearson Chi-
square was used, or the Fisher’s exact test was used if there
was sparse distribution. Those clinical characteristics that
were signiﬁcantly correlated to the outcome by univariate
analysis (P-value < 0.05) were then ﬁtted into the logistic
regression model for multivariate analysis of variances to
assess the strength of the risk factors.
All statistical analyses were conducted using SAS (SAS
Institute Inc, Cary, NC, USA. SAS (r) Proprietary Software
9.2 (TS2M3)).
3. Results
3.1. Preoperative and Intraoperative Data. Between January
1, 2006 and December 31, 2009, a total of 147 patients
(135 appendiceal cancer, 12 colorectal cancer) were treated.
There were 68 men and 79 women. The mean age was
49.9 years (range, 23–64). Data on patient characteristics,
quantitative prognosis indicators, peritonectomies, visceral
resections, and intraoperative treatments are summarized in
Table 1. In these 147 patients, 424 peritonectomy procedures
wereperformedwithameanof3peritonectomiesperpatient
(range 0 to 5). In 18 patients (12%), no peritonectomy
procedures were performed and 32 patients (22%) had all 5
peritonectomy procedures. A total of 455 visceral resections
were performed. The mean number per patient was 3.1 with
arangeof0to7.Greateromentectomywasperformedin144
patients (98%) and 4 (3%) had a total or partial gastrectomy.
In two patients (1%), there were no visceral resections.
Thirty-four(23%)had2visceralresectionsandanadditional
34patients(23%)had3visceralresections.Thetotalnumber
of anastomoses in all patients was 112 with a mean of 0.76
per patient (range 0–4). The most common anastomosis was
a colorectal anastomosis performed in 56 patients (38%).
There was a total of 43 ostomies (29%) performed. Thirty
(20%) were diverting ileostomies to protect a colorectal
anastomosis and, 13 (9%) were permanent-end ileostomies
following total abdominal colectomy.
In 39 patients (27%), no blood replacement in the
operating room occurred. Only 5 patients had more than
six units transfused. Sixty-seven patients (46%) received
fresh frozen plasma and, 16 (11%) patients had more than
four units. All 147 patients were treated with HIPEC and
intravenous 5-FU in the operating room. In 65 patients
(44%), EPIC was used in the postoperative period (Table 1).
3.2. Adverse Events. In these 147 patients, there was a
single postoperative death (0.7%). This patient developedInternational Journal of Surgical Oncology 5
Table 3: Univariate and multivariate analysis (gastrointestinal events).
Gastrointestinal events I–IV univariate analysis Gastrointestinal events I–IV multivariate analysis
Yes N = 25 No N = 122 P Value∗/OR
(95% CI) Odds Ratio P Value
Gender
Male 12 56 0.8480 NT∗∗
Female 13 66 0.9 (0.4,2.2)
Age
≤50 year 14 58 0.4408 NT
>50 year 11 64 0.7 (0.3,1.7)
Location
Appendix 22 113 0.4297 NT
Colorectal 3 9 1.7 (0.4,6.8)
Grade
Grade 1 5 56 0.0166 0.4(0.1, 1.3) 0.1345
Grades 2-3 20 66 0.3 (0.1,0.8)
Prior Surgical Score
0–2 23 110 1.0000 NT
3–5 2 12 0.8 (0.2,3.8)
Peritoneal Cancer Index (4 groups)
0–10 3 28 Reference
NT 11–20 6 34 0.7220
1.6 (0.4,7.2)
21–30 7 46 0.7384
1.4 (0.3,5.9)
31–39 9 14 0.0100
6.0 (1.4,25.7)
Peritoneal Cancer Index (2 groups B)
0–30 16 108 0.0049 2.8 (0.9,8.4) 0.0586
31+ 9 14 4.3 (1.6,11.7)
Completeness of Cytoreduction
Complete 18 107 0.0625 NT
Incomplete 7 15 2.8 (1.0,7.7)
Peritonectomy Procedure
Pelvic 21 102 1.0000
1.0 (0.3,3.3) NT
Right Upper Quardrant 19 90 0.8166
1.1 (0.4,3.1) NT
Left Upper Quardrant 11 61 0.5846
0.8 (0.3,1.9) NT
Omental Bursa 12 58 0.9666
1.0 (0.4,2.4) NT
Anterior Abdominal
Wall 11 39 0.2473
1.7 (0.7,4.0) NT
Peritonectomy Procedure per patient
0–2 8 47 0.5391 NT
3–5 17 75 1.3 (0.5,3.3)
Visceral Resections Performed
Omentectomy 24 120 0.4308
0.4 (0.03,4.6) NT
Splenectomy 15 69 0.7513
1.2 (0.5,2.8) NT
Rectosigmoid colon 14 43 0.0524
2.3 (0.98,5.6) NT6 International Journal of Surgical Oncology
Table 3: Continued.
Gastrointestinal events I–IV univariate analysis Gastrointestinal events I–IV multivariate analysis
Yes N = 25 No N = 122 P Value∗/OR
(95% CI) Odds Ratio P Value
Right colon resection 15 55 0.1736
1.8 (0.8,4.4) NT
Hysterectomy 4 43 0.0601
0.3 (0.1,1.1) NT
Small bowel resection 9 20 0.0493
2.9 (1.1,7.4) 1.3 (0.4,4.2) 0.6202
Transverse colon 5 15 0.3377
1.8 (0.6,5.5) NT
Gastrectomy 2 2 0.1343
5.2 (0.7,38.9) NT
Visceral Resections Performed per patient
0–2 7 49 0.2539 NT
3–7 18 73 1.7 (0.7,4.4)
Anastomoses performed
Esophago-jejunal 1 1 0.3122
5.0 (0.3,83.4) NT
Small bowel 7 15 0.0605
2.8 (1.0,7.7) NT
Ileocolic 7 22 0.2741
1.8 (0.7,4.7) NT
Colocolic 1 2 0.4308
2.5 (0.2,28.7) NT
Colorectal 14 42 0.0430
2.4 (1.0,5.8) 1.4 (0.5,3.8) 0.4986
Anastomoses performed per patient
0–2 21 118 0.0288 1.9 (0.3,11.8) 0.4616
3–5 4 4 5.6 (1.3,24.2)
Ostomies performed
None 15 89 reference
Diverting ileostomy 8 22 0.1172
2.2 (0.8,5.7) NT
End ileostomy 2 11 1.0000
1.1 (0.2,5.4) NT
Blood replacement
None 7 32 reference
Blood 1–3 8 60 0.3752
0.6 (0.2,1.8) NT
Blood 4–6 9 26 0.4178
1.6 (0.5,4.8) NT
Blood > 61 4 1.0000
1.1 (0.1,11.8) NT
Fresh frozen plasma replacement
None 13 67 reference
Plasma 1–4 7 44 0.6953
0.8 (0.3,2.2) NT
Plasma > 45 1 1 0.1724
2.3 (0.7,7.9) NTInternational Journal of Surgical Oncology 7
Table 3: Continued.
Gastrointestinal events I–IV univariate analysis Gastrointestinal events I–IV multivariate analysis
Yes N = 25 No N = 122 P Value∗/OR
(95% CI) Odds Ratio P Value
Time in operating room (hours)
0–6 2 8 reference
7–12 18 106 0.6445
0.7 (0.1,3.5) NT
>12 5 8 0.450
2.3 (0.4,16.9) NT
Chemotherapy treatment
HIPEC only 10 69 0.2314 NT
HIPEC plus EPIC 13 52 1.7 (0.7,4.2)
Unknown 2 1
∗: Pearson Chi-square, or Fisher’s exact test if sparse distribution. ∗∗: NT means Not Tested in multivariate modeling due to non signiﬁcant univariate test.
a profound neutropenia followed by systemic inﬂammatory
response syndrome and multiorgan failure. The overall
incidence of gastrointestinal adverse events was 17%. Thirty-
ﬁve gastrointestinal events occurred in 25 patients. Nine
patients had more than one gastrointestinal event. All the
gastrointestinal events observed grade I through IV are
summarized in Table 2.
The incidence of grade III and IV events was 8% with
15 events observed in 12 patients. There were 5 grade I
gastrointestinal events (4 pancreatitis and 1 chyle leak) that
occurredin5patients.Therewere15gradeIIgastrointestinal
events (4 pancreatitis, 1 prolonged ileus, 7 nausea/vomiting,
and 1 diarrhea) that occurred in 11 patients. Four grade
III gastrointestinal events (4 nausea/vomiting) occurred in
4 patients. Eleven grade IV gastrointestinal events (3 anasto-
motic failures, 3 ﬁstulas, 1 pancreatic ﬁstula, 1 pancreatitis, 1
bile leak, 1 small bowel obstruction, and 1 nausea/vomiting)
occurredin8patientsandallbuttworequiredareturntothe
operating room.
By univariate analysis, the following variables were pro-
ven to have a statistically signiﬁcant correlation with gastroi-
ntestinalmorbidity(Table 3):histologicalgrade(P=0.0166),
PCI (P=0.0049), small bowel resection (P=0.0493), perfor-
manceofacolorectalanastomosis(P=0.0430)andthenum-
ber of anastomoses performed per patient (P = 0.0288).
On multivariate analysis using the logistic regression
model, the PCI was shown to be the only independent risk
factor for gastrointestinal complications (P = 0.0586).
InpatientswhohadHIPECplusEPIC,anadditionalfour
treatments with intraperitoneal 5-ﬂuorouracil were given
on postoperative days 1–4. Thirteen of 52 patients (25%)
had a grade I–IV complication. Ten of 69 patients (14%)
who had HIPEC only were observed to have a grade I–IV
complication. As shown in Table 3, this was not signiﬁcant
by a univariate (P = 0.2314) or by the multivariate analysis.
4. Discussion
At our institution the management of peritoneal surface
malignancy requires an integration of extensive surgery
combined with intraperitoneal chemotherapy administered
as a planed part of the surgical procedures [31]. The
aim of this combined treatment modality is to remove all
macroscopic tumor nodules and any adhesions between the
bowel loops, in order to allow chemotherapeutic agents
to be uniformly distributed within the peritoneal cavity
to eradicate any microscopic tumor deposits. The poten-
tial advantages of using HIPEC compared to standard
intravenous chemotherapy include an increased exposure
to chemotherapeutic drugs at the peritoneal surface, an
increase of drug penetration into the tissues, a synergistic
eﬀect of hyperthermia with systemic chemotherapy, and an
independent cytotoxic eﬀect of hyperthermia [32].
It is clear, however, that the eﬀects of this regional
chemotherapy are not limited to the peritoneal space. The
profound eﬀect that these treatments have on wound healing
isshownbytheincreasedincidenceofgastrointestinalevents.
This paper represents the eﬀort of our group to identify
gastrointestinal events in patients with peritoneal surface
malignancy and begin to understand their causes.
We found that our overall incidence of gastrointestinal
events was 17% (grade I–IV), in that 35 gastrointestinal
events occurred in 25 of the 147 patients. There was
often more than one gastrointestinal event per patient. The
incidence of grade III and IV gastrointestinal events was 8%.
Our data is compared to those reported by other
authors in Table 4. We have calculated the incidence of
gastrointestinal events (grades III-IV) in Glehen, Kusamura,
and Hansson’s manuscripts by dividing the total number of
eventsbythetotalnumberofpatients.InYoussefmanuscript
and in our data, we were able to calculate the incidence
of events per patient (Table 4). Glehen et al. conducted a
study of 207 patients treated by CRS and HIPEC with the
closed abdominal technique [23]. The overall postoperative
morbidity rate including all grades III-IV was 24.5%. They
had 14 digestive ﬁstulas, 11 cases of prolonged ileus, and
5 intraperitoneal abscesses. The presence of digestive ﬁstula
was signiﬁcantly associated with the duration of surgery
and the number of anastomoses in the univariate analysis.
Kusamura et al. conducted a study of 205 patients treated8 International Journal of Surgical Oncology
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by CRS and HIPEC with the closed abdominal technique
[24]. The overall postoperative morbidity rate including all
grade III-IV was 12%. They had 17 anastomotic leaks, 6
digestive perforations, 1 biliary ﬁstula, 2 pancreatic ﬁstulas,
and 4 ileus/gastric stasis. The most severe complications
in their series were intestinal leakage due to anastomotic
insuﬃciency and/or intestinal perforation. This morbidity
constituted approximately 70% of all cases with major mor-
bidity. The rate of ﬁstula in the series was 11%. They found
in the multivariate analysis that the extent of cytoreduction
(levels 1 and 2 versus 3) and CDDP for IPHP dose ≥ 240mg
were independent risk factors for major morbidity.
Hansson et al. conducted a study of 123 patients treated
by CRS and HIPEC and observed grade III-IV adverse
events in 51 patients (41%) [25]. In multivariate analyses,
grade III-IV adverse events were associated with stoma
formation, duration of surgery, perioperative blood loss,
and peritoneal cancer index. Among the gastrointestinal
events, 7 anastomotic leaks, 11 digestive tract perforations,
1 pancreatitis, 1 bile leak, and 3 prolonged ileus occurred.
Youssefetal.conductedastudyof456patientswithpseu-
domyxoma peritonei syndrome of appendiceal origin [26];
grade III-IV morbidity was 7%. Seven anastomotic leaks, 5
pancreatic complications, and 8 intestinal ﬁstulas were repo-
rted. An analysis of prognosis risk factors was not provided.
In our study, we found that the histological grade, PCI,
small bowel resection, colorectal anastomoses performed,
and the number of anastomoses performed per patient had a
statistically signiﬁcant correlation with gastrointestinal mor-
bidity; by multivariate analysis only, the PCI was an inde-
pendent risk factor for gastrointestinal complications. These
data suggest that CRS combined with a standardized treat-
ment with perioperative chemotherapy is a reasonable safe
treatment for selected patients with peritoneal surface malig-
nancy. There is an acceptable gastrointestinal morbidity as
compared with modern series of pancreatic-duodenectomy,
gastrectomy for cancer, or other multiorgan resections.
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